Free shipping on orders of $75+ for patients.
Doctors must be logged in to view professional pricing.
You are viewing professional pricing.

Spotlights & Highlights 2023

(I-MED Pharma)

And that’s a wrap! As 2023 comes to a close, we look back on another incredible year full of new milestones.

Product launches

Starting off 2023 on the right foot, we released a 30-day format of our I-VU® OMEGA-3 PLUS capsules, creating a more affordable way for patients to try our omega-3 for dry eyes capsule supplement. With a total of 1824 mg of the most important Omega-3 fatty acids per daily dose, I-VU® OMEGA-3 PLUS helps to provide relief and improve symptoms of Dry Eye Syndrome, including support for proper tear function in adults.

In July, we relaunched our iconic I-VU® OMEGA-3 liquid supplement with an increased amount of DPA. It is a great alternative to our capsule format with a total of 2340 mg of essential omega-3s in one daily dose, plus vitamin D3 & GLA. I-VU® OMEGA-3 helps relieve symptoms of dry eye syndrome while supporting proper tear function in adults and is also recommended for the maintenance of good health and helps to support cardiovascular health, cognitive health, immune function and the development and maintenance of bones and teeth.

Advancing the science of dry eye with innovative studiesScientific studies

In our continuous pursuit of advancing the science of dry, we put a large emphasis on supporting our products with scientific studies. This year, we released two new studies outlining the excellent performance of our signature lines: I-DROP® and I-LID ’N LASH®.

The study titled “Evaluating Viscosity and Tear Breakup Time of Contemporary Commercial Ocular Lubricants on an In Vitro Eye Model” focused on our I-DROP® line and demonstrated the incredible performance of our preservative-free artificial tears compared to competitor products.

The study titled “I-LID ’N LASH® PLUS: a safe and effective product in managing Demodicosis in vivo” was conducted on I-LID ’N LASH® PLUS, our ocular hygiene cleanser with 5% tea tree oil. The study demonstrates that it is both effective at managing Demodicosis by reducing the collarettes/cylindrical dandruff counts, improving tear film stability and is also safe for the meibomian glands.

Leadership team

We are pleased to have welcomed Paul Donnelly to the I-MED Pharma team in the position of Director of Quality Assurance and Regulatory Affairs. As I-MED Pharma continues to grow, this department plays a significant role in ensuring we continue our quest towards excellence. Paul has a comprehensive understanding of global regulations and standards governing the industry and is passionate about the benefits that compliance brings to I-MED. He knows that by adhering to industry standards and regulations, companies can improve the quality of their products and maintain their reputation in the market.


As the 2023 tradeshow season comes to an end, we are thrilled to look back on the great conversations, participation, and community that was involved in this year’s events. We met so many people and had a great time at tradeshows this year from all across Canada

Events like this give us a chance to meet current and potential customers, and we cherish the connections and new relationships we get to create.

Giving back

Part of our brand DNA is giving back. At I-MED Pharma, we are continuously honored to be in a position where we can make a difference in our community. We’ve donated to various charities and communities in need throughout the year. We are proud to support these important companies to help keep the conversation going around ocular health.

As the saying goes, teamwork makes the dream work! Our people, industry partners, customers, and dry eye patients play an integral role in I-MED Pharma’s success around the world. Our vision is to be the most important dry eye and ocular surface disease company in the world. To do this, we continually research and develop the most effective and advanced solutions for dry eye disease. Our mission is that we are devoted to pushing the boundaries, enriching lives, and shaping the future of eye care, while bringing complete relief to dry eye and ocular surface disease patients worldwide. It is with the help and support of these relationships that we can succeed and grow as the leader in dry eye disease.

From all of us at I-MED Pharma, have a safe and happy holiday season and all the very best for 2024.

See you next year!